Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Gastrointestinal 2Thoracic 1Sarcoma 1Genitourinary 1CNS 1

Conditions

Colorectal Neoplasms 19Colonic Neoplasms 9Pancreatic Neoplasms 8Esophageal Neoplasms 7Stomach Neoplasms 6Rectal Neoplasms 5Adenocarcinoma Of Esophagus 5Ovarian Neoplasms 4Neoplasm Metastasis 4Lymphoma, Large B-Cell, Diffuse 4Cholangiocarcinoma 4Carcinoma, Non-Small-Cell Lung 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 3Endometrial Neoplasms 3Adenocarcinoma 3Recurrence 2Lymphoma, Follicular 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Small Bowel Adenocarcinoma 1Prostatic Neoplasms 1

Interventions

pembrolizumab 14Paclitaxel 13Carboplatin 12Bevacizumab 7Specimen Handling 6Cisplatin 6olaparib 5Taxes 5Fulvestrant 5Nivolumab 4Megestrol Acetate 4Magnetic Resonance Spectroscopy 4Biopsy 4palbociclib 3durvalumab 3Oxaliplatin 3Leucovorin 3Letrozole 3Immunoglobulin G 3Fluorouracil 3Doxorubicin 3Docetaxel 3Disulfides 3trastuzumab deruxtecan 2ribociclib 2pertuzumab 2lenvatinib 2ipatasertib 2dostarlimab 2capivasertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Oxaliplatin × 30 days × Clear all
NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05919264 2026-05-28

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Parabilis Medicines, Inc.

Phase 1/2 Recruiting
595 enrolled
CNSGastrointestinalGenitourinaryGynecologicSarcoma

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡